The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Biomedical Applications of a Novel Class of High-Affinity Peptides
Abstract
Conspectus Most therapeutic peptides available on the market today are naturally occurring hormones or protein fragments that were serendipitously discovered to possess therapeutic effects. However, the limited repertoire of available natural resources presents difficulties for the development of new peptide drug candidates. Traditional peptides possess several shortcomings that must be addressed for biomedical applications, including relatively low affinity or specificity toward biological targets compared to antibody- and protein scaffold-based affinity molecules, poor in vivo stability owing to rapid enzymatic degradation, and rapid clearance from circulation owing to their small size. Going forward, it will be increasingly important for scientists to develop novel classes of high-affinity and -specificity peptides against desired targets that mitigate these limitations while remaining compatible with pharmaceutical manufacturing processes. Recently, several highly constrained, artificial cyclic peptides have emerged as platforms capable of generating high-affinity peptide binders against various disease-associated protein targets by combining with phage or mRNA display method, some of which have entered clinical trials. In contrast, although linear peptides are relatively easy to synthesize cost-effectively and modify site-specifically at either N- or C-termini compared to cyclic peptides, there have been few linear peptide-based platforms that can provide high-affinity and -specificity peptide binders. In this Account, we describe the creation and development of a novel class of high-affinity peptides, termed “aptide”—from the Latin word “ apt us ” meaning “to fit” and “pep tide ”—and summarize their biomedical applications. In the first part, we consider the design and creation of aptides, with a focus on their unique structural features and binding mode, and address screening and identification of target protein-specific aptides. We also discuss advantages of the aptide platform over ordinary linear peptides lacking preorganized structures in terms of the affinity and specificity of identified peptide binders against target molecules. In the second part, we describe the potential biomedical applications of various target-specific aptides, ranging from imaging and therapy to theranostics, according to the types of aptides and diseases. We show that certain aptides can not only bind to a target protein but also inhibit its biological function, thereby showing potential as therapeutics per se . Further, aptides specific for cancer-associated protein antigens can be used as escort molecules or targeting ligands for delivery of chemotherapeutics, cytokine proteins, and nanomedicines, such as liposomes and magnetic particles, to tumors, thereby substantially improving therapeutic effects. Finally, we present a strategy capable of overcoming the critical issue of short blood circulation time associated with most peptides by constructing a hybrid system between an aptide and a hapten cotinine-specific antibody.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although peptide drugs can enter cells to restore p53 function, it is difficult to maintain stability and function after entering the human body.505,506”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [506]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
How Big Is Too Big for Cell Permeability?
Matsson, P., & Kihlberg, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00237 · Cited by 303
Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging
Park, J., Kim, S., Saw, P. E., Lee, I.-H., Yu, M. K., Kim, M., Lee, K., Kim, Y.-C., Jeong, Y. Y., & Jon, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.08.029 · Cited by 48
Self-citation
Research works printed but not linked: 77
- 10.1002/anie.201107894 · DOI
- 10.1158/0008-5472.CAN-13-2187 · doi:10.1158/0008-5472.can-13-2187
- 10.1002/anie.201811509 · doi:10.1002/anie.201811509
- 10.1038/417584a · DOI
- 10.1057/jcb.2010.37 · doi:10.1057/jcb.2010.37
- DePalma A., 2015, Genetic Engineering & Biotechnology News, 35, 24, 10.1089/gen.35.09.13 · doi:10.1089/gen.35.09.13
- 10.3390/ijms20246289 · DOI
- 10.1016/j.drudis.2009.10.009 · DOI · Paper page
- 10.1016/j.coph.2008.06.002 · DOI · Paper page
- 10.1002/jcph.407 · DOI
- 10.1016/j.canlet.2021.03.015 · DOI
- 10.1126/sciadv.aay2174 · DOI
- 10.1073/pnas.2024102118 · DOI
- 10.1038/s41573-020-00135-8 · DOI · Paper page
- 10.1038/s41570-019-0159-2 · DOI · Paper page
- 10.1016/j.cbpa.2017.02.006 · DOI · Paper page
- 10.1016/S0169-409X(02)00179-5 · DOI · Paper page
- 10.1021/acs.accounts.7b00184 · DOI · Paper page
- 10.1002/chem.201300247 · DOI
- 10.1007/s13238-019-0639-7 · DOI · Paper page
- 10.1038/nmeth877 · DOI · Paper page
- 10.1038/nchembio.184 · DOI · Paper page
- 10.4062/biomolther.2019.082 · DOI
- 10.15212/bioi-2020-0033 · doi:10.15212/bioi-2020-0033
- 10.1016/S0092-8674(05)80070-4 · DOI · Paper page
- 10.1073/pnas.091100898 · DOI · Paper page
- 10.1021/cr960065d · DOI · Paper page
- 10.1007/s12033-019-00156-8 · DOI
- 10.1126/science.4001944 · DOI · Paper page
- 10.1088/0957-4484/27/48/48LT01 · DOI
- 10.1021/acs.molpharmaceut.7b00520 · DOI
- 10.1002/adhm.201500190 · DOI
- 10.1016/j.biomaterials.2013.12.031 · DOI
- 10.1016/j.jconrel.2017.04.036 · doi:10.1016/j.jconrel.2017.04.036
- 10.1039/c3tb20613k · DOI
- 10.1016/j.jconrel.2014.07.006 · DOI
- 10.1039/C6MD00696E · doi:10.1039/c6md00696e
- 10.1002/cbic.201402450 · doi:10.1002/cbic.201402450
- 10.1002/anie.201404750 · DOI
- 10.1056/NEJM199412013312203 · DOI · Paper page
- 10.1038/nm0603-669 · DOI · Paper page
- Miller J. W., 1994, Am. J. Pathol., 145, 574
- 10.1074/jbc.273.32.20556 · DOI · Paper page
- 10.1016/j.ophtha.2005.02.007 · DOI · Paper page
- 10.1006/jmbi.1999.3192 · DOI · Paper page
- 10.1038/nrc2734 · DOI · Paper page
- 10.1038/nri1995 · DOI · Paper page
- 10.3390/molecules24050927 · DOI · Paper page
- 10.3389/fphar.2020.00697 · DOI · Paper page
- 10.1016/j.ejphar.2020.173107 · DOI
- 10.1084/jem.20191761 · DOI
- 10.1021/acsnano.8b02330 · DOI
- 10.1016/j.jconrel.2021.02.022 · DOI
- 10.1002/ijc.2910590507 · DOI · Paper page
- 10.1002/ijc.21677 · DOI · Paper page
- 10.1016/j.pharmthera.2016.07.012 · DOI
- 10.1158/1541-7786.MCR-19-0582 · DOI · Paper page
- 10.1039/D0CS00556H · DOI · Paper page
- 10.1039/c3tb20815j · DOI
- 10.1016/j.jconrel.2014.01.015 · DOI
- 10.1172/JCI65624 · DOI
- 10.1038/ncponc0426 · DOI
- 10.1038/bjc.1996.652 · DOI
- 10.1146/annurev-bioeng-071812-152409 · DOI · Paper page
- 10.1039/C2CS15261D · DOI · Paper page
- 10.2147/IJN.S53717 · DOI · Paper page
- 10.1038/nature06917 · DOI · Paper page
- 10.1021/ar200019c · DOI · Paper page
- 10.2217/17435889.3.2.137 · DOI · Paper page
- 10.7150/thno.44948 · DOI
- 10.7150/thno.8343 · DOI
- 10.1007/s40262-013-0079-0 · DOI · Paper page
- 10.4161/mabs.21024 · DOI
- Bhat A., 2013, Fusion Protein Technologies for Biopharmaceuticals, 571, 10.1002/9781118354599.ch38 · doi:10.1002/9781118354599.ch38
- 10.1016/j.ccr.2004.09.030 · DOI · Paper page
- 10.1021/acs.molpharmaceut.8b00924 · doi:10.1021/acs.molpharmaceut.8b00924
- 10.3858/emm.2012.44.9.063 · doi:10.3858/emm.2012.44.9.063
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Metadata
- Authors
- Saw, P. E., Xu, X., Kim, S., & Jon, S.
- Affiliations
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiang West Road, Guangzhou 510120, P.R. China
- Center for Convergence Bioceramic Materials, Korea Institute of Ceramic Engineering and Technology (KICET), Cheongju-si 28160, Republic of Korea
- Center for Precision Bio-Nanomedicine, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon 34141, South Korea
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-08-18
- Volume
- 54
- Issue
- 18
- Pages
- 3576-3592
- ISSN
- 0001-4842
- 1520-4898
- Cited by
- 36
- References
- 3
- Language
- en
- Licence
- Funders
- National Research Foundation of Korea (NRF-2018R1A3B1052661, NRF-2020R1F1A1064124)
- National Natural Science Foundation of China (81803020, 82072930)
- Guangdong Province (2021B1515020066)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.